Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TRAX | 8-K | bullish | 7/10 | First Tracks Biotherapeutics announced positive top-line results from Cohort 1 of ANB033's Phase 1b gluten-challenge tri | Oct 13, 2026 |
| IBIO | 8-K | bullish | 5/10 | iBio released preclinical body-composition data from an obese NHP study of IBIO-610, a first-in-class Activin E antibody | Oct 13, 2026 |
| JNJ | 8-K | mixed | 6/10 | JNJ reported Q3 2026 adjusted EPS of $2.59, a -11.2% miss vs consensus of $2.92, and revenue of $25.4B vs $26.43B consen | Oct 13, 2026 |
| ONCY | 8-K | neutral | 3/10 | Oncolytics Biotech filed an 8-K announcing updates to its intellectual property portfolio for pelareorep. A new method-o | Oct 13, 2026 |
| MIRM | 8-K | bullish | 7/10 | Mirum Pharmaceuticals announced positive topline results from the Phase 3 EXPAND study of LIVMARLI (maralixibat) in ultr | Oct 13, 2026 |
| CDT | 8-K | bearish | 7/10 | CDT Equity Inc. issued a $6,750,000 senior secured convertible note to J.J. Astor & Co., receiving $3,000,000 in the fir | Oct 13, 2026 |
| HRMY | 8-K | neutral | 3/10 | Harmony Biosciences announced a planned CEO transition: current CEO Jeffrey Dayno will retire on December 31, 2026, and | Oct 13, 2026 |
| ADIA | 8-K | neutral | 3/10 | Adia Med, Inc. fully repaid and discharged a $1,000,000 unsecured revolving line of credit from its CEO, Larry Powalisz, | Oct 13, 2026 |
| ZTS | 8-K | neutral | 2/10 | Zoetis appointed Iris Knobloch to its Board of Directors, effective December 1, 2026, increasing board size from 12 to 1 | Oct 13, 2026 |
| ADCT | 8-K | bullish | 7/10 | ADC Therapeutics announced a comprehensive capital restructuring: an $86.6M PIPE (12.9M shares at $1.42 + 48.1M pre-fund | Oct 13, 2026 |
| NRIX | 8-K | bullish | 7/10 | Nurix Therapeutics reported Q3 2026 revenue of $673.1M (vs $7.9M YoY) and net income of $549.8M ($4.73 diluted EPS), mas | Oct 13, 2026 |
| AVBP | 8-K | neutral | 4/10 | ArriVent BioPharma dosed the first patient in a Phase 1 U.S. trial for ARR-002, a novel first-in-class MUC16/NaPi2b dual | Oct 13, 2026 |
| ICCC | 8-K | bullish | 6/10 | ImmuCell announced preliminary, unaudited Q3 2026 product sales of $8.0 million, a 46% increase YoY, driven by broad-bas | Oct 13, 2026 |
| BBIO | 8-K | bullish | 7/10 | BridgeBio announced FDA acceptance and Priority Review of its NDA for oral infigratinib for children with achondroplasia | Oct 13, 2026 |
| ZBIO | 8-K | neutral | 4/10 | Zenas BioPharma presented new obexelimab data from the Phase 3 INDIGO open-label extension at the 6th International Symp | Oct 13, 2026 |
| SBFM | 8-K | bearish | 6/10 | Sunshine Biopharma closed a best-efforts public offering raising approximately $6.0 million in gross proceeds via 10,909 | Oct 9, 2026 |
| QUCY | 8-K | neutral | 4/10 | Quantum Cyber N.V. entered into an at-the-market (ATM) sales agreement with Titan Partners Securities LLC to sell up to | Oct 9, 2026 |
| VTGN | 8-K | neutral | 3/10 | Vistagen Therapeutics adopted an amended and restated Executive Severance Plan on October 7, 2026, expanding severance b | Oct 9, 2026 |
| ARTL | 8-K | bearish | 5/10 | Artelo Biosciences disclosed that it was among ~180 Nasdaq-listed companies initially identified as having a market valu | Oct 9, 2026 |
| MBRX | 8-K | neutral | 4/10 | Moleculin Biotech held its 2026 Annual Meeting on October 9, 2026. Stockholders approved an amendment to the 2024 Stock | Oct 9, 2026 |
| PCVX | 8-K | bearish | 6/10 | Vaxcyte entered into a First Supplemental Indenture to issue $575M aggregate principal amount of 1.50% Convertible Senio | Oct 9, 2026 |
| BIAF | 8-K | bearish | 6/10 | bioAffinity Technologies entered into a placement agency agreement and securities purchase agreement on October 8, 2026, | Oct 9, 2026 |
| HEPA | 8-K | mixed | 6/10 | Hepion Pharmaceuticals completed the acquisition of Gravitas Life Sciences (GLS), a clinical-stage biotech developing op | Oct 9, 2026 |
| TCRT | 8-K | bearish | 7/10 | Alaunos Therapeutics received a delisting notice from Nasdaq on October 5, 2026, for failing to maintain the minimum $2. | Oct 9, 2026 |
| MYGN | 8-K | neutral | 3/10 | Myriad Genetics filed an 8-K reporting the separation of Chief Commercial Officer Brian Donnelly, effective September 21 | Oct 9, 2026 |
| CTTH | 8-K | neutral | 3/10 | CTT Pharmaceutical Holdings filed an 8-K with Item 4.01 (Change in Accountant), attaching a letter from predecessor audi | Oct 9, 2026 |
| CRVO | 8-K | neutral | 2/10 | CervoMed Inc. filed an 8-K under Item 7.01 to disclose that an investor presentation is available on its website. The fi | Oct 9, 2026 |
| LNAI | 8-K | bearish | 6/10 | Lunai Bioworks submitted a formal request to Nasdaq on October 9, 2026, asking for an immediate trading suspension in it | Oct 9, 2026 |
| EXOZ | 8-K | neutral | 2/10 | EXOZYMES INC. filed an 8-K attaching an investor presentation dated October 6, 2026, that may be provided to investment | Oct 9, 2026 |
| JAZZ | 8-K | neutral | 2/10 | Jazz Pharmaceuticals disclosed that EVP and Chief Commercial Officer Samantha Pearce plans to retire, effective upon app | Oct 9, 2026 |